The Washington Post (9/12, Kornfield) reports, “In a year-long evaluation of more than 400 patients…at three MindPeace ketamine clinics in Virginia, researchers found a significant reduction in symptoms of depression” after receiving intravenous (IV) ketamine. The findings, published online Sept. 12 in the Journal of Clinical Psychiatry, revealed that “72 percent of patients saw improvement in their mood and 38 percent were symptom-free after 10 infusions.”  CNN (9/12, Dillinger, McPhillips) reports, “Half of the patients who had suicidal ideation were in remission after six weeks, and there was a 30% reduction in anxiety symptoms over the course of treatment,” the study found. What’s more, “response rates in the initial phase of treatment were similar to those of oral medication and transcranial magnetic stimulation for treatment-resistant depression, the researchers say.” (SOURCE: APA Headlines)